Bipolar I Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Bipolar I disorder is a persistent mental health condition characterized by alternating phases of heightened mood, known as mania, and low mood, known as depression. Mania is described as a distinct period of excessively elevated, expansive, or irritable mood, accompanied by increased activity or energy, lasting at least a week and occurring most days, often requiring hospitalization if shorter. This disorder affects approximately 1 in 100 adults, posing a significant public health concern. It typically manifests with a mix of manic and depressive symptoms, leading to severe disruptions in mood lasting weeks or months, impacting various aspects of daily life and functioning. While the monoaminergic neurotransmitter systems—such as serotonin, norepinephrine, and dopamine—have been central to theories and research on mood disorder origins, no single neurotransmitter system dysfunction has been conclusively identified in bipolar disorder despite evidence suggesting their involvement. In the long-term course of bipolar I disorder, most episodes lack mood-incongruent psychotic symptoms (MIS), although the majority of patients experience them. Those with MIS tend to be male, require treatment at a younger age, rarely exhibit initial symptoms after age 50, have more relatives with schizophrenia, retire earlier due to disability, and are less likely to have stable partnerships compared to those without MIS. Lithium remains the primary treatment for managing bipolar I disorder, recognized for its efficacy in preventing suicide among bipolar patients. In June 2021, the FDA approved Lybalvi® (olanzapine/samidorphan) for various indications, including acute manic episodes or mixed features in adults with schizophrenia or bipolar I disorder.
Thelansis’s “Bipolar I Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bipolar I Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Bipolar I Disorder across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Bipolar I Disorder Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment